JP2016525092A5 - - Google Patents

Download PDF

Info

Publication number
JP2016525092A5
JP2016525092A5 JP2016524330A JP2016524330A JP2016525092A5 JP 2016525092 A5 JP2016525092 A5 JP 2016525092A5 JP 2016524330 A JP2016524330 A JP 2016524330A JP 2016524330 A JP2016524330 A JP 2016524330A JP 2016525092 A5 JP2016525092 A5 JP 2016525092A5
Authority
JP
Japan
Prior art keywords
pyrrole
methyl
carboxylate
octahydropyrrolo
hexafluoropropan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016524330A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016525092A (ja
JP6647592B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/045145 external-priority patent/WO2015003002A1/en
Publication of JP2016525092A publication Critical patent/JP2016525092A/ja
Publication of JP2016525092A5 publication Critical patent/JP2016525092A5/ja
Application granted granted Critical
Publication of JP6647592B2 publication Critical patent/JP6647592B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016524330A 2013-07-03 2014-07-01 ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用 Expired - Fee Related JP6647592B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361842543P 2013-07-03 2013-07-03
US61/842,543 2013-07-03
PCT/US2014/045145 WO2015003002A1 (en) 2013-07-03 2014-07-01 Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof

Publications (3)

Publication Number Publication Date
JP2016525092A JP2016525092A (ja) 2016-08-22
JP2016525092A5 true JP2016525092A5 (enExample) 2017-08-10
JP6647592B2 JP6647592B2 (ja) 2020-02-14

Family

ID=52144176

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016524330A Expired - Fee Related JP6647592B2 (ja) 2013-07-03 2014-07-01 ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用

Country Status (7)

Country Link
US (1) US9828379B2 (enExample)
EP (1) EP3016653A4 (enExample)
JP (1) JP6647592B2 (enExample)
CN (1) CN105517547A (enExample)
CA (1) CA2917050A1 (enExample)
MX (1) MX2015017961A (enExample)
WO (1) WO2015003002A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013207252B2 (en) 2012-01-06 2016-06-09 H.Lundbeck A/S Carbamate compounds and pharmaceutical compositions thereof
CA2917050A1 (en) 2013-07-03 2015-01-08 Todd K. Jones Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
ES2823049T3 (es) * 2015-07-31 2021-05-05 Pfizer Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-ilo y derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ilo como inhibidores de MAGL
WO2017143283A1 (en) 2016-02-19 2017-08-24 Abide Therapeutics, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
US10781211B2 (en) 2016-05-12 2020-09-22 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
JP7042804B2 (ja) * 2016-09-19 2022-03-28 ルンドベック ラ ホーヤ リサーチ センター,インク. ピペラジンカルバメート、及びその製造と使用の方法
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
ES2966939T3 (es) 2016-11-16 2024-04-25 H Lundbeck As Una forma cristalina de un inhibidor de MAGL
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CN110290791A (zh) * 2016-11-16 2019-09-27 灵北拉荷亚研究中心公司 药物制剂
RU2720203C1 (ru) * 2017-01-20 2020-04-27 Пфайзер Инк. 1,1,1-трифтор-3-гидроксипропан-2-илкарбаматные производные как ингибиторы magl
CN117466868A (zh) * 2017-03-13 2024-01-30 灵北拉荷亚研究中心公司 双重magl和faah抑制剂
JOP20200022A1 (ar) * 2017-08-29 2020-02-02 Lundbeck La Jolla Research Center Inc مركبات حلقية لولبية وطرق تصنيعها واستخدامها
MX2020002251A (es) 2017-08-29 2020-07-20 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso.
CN111148746B (zh) * 2017-09-29 2022-08-05 武田药品工业株式会社 杂环化合物
US11332453B2 (en) 2018-05-15 2022-05-17 H. Lundbeck A/S MAGL inhibitors
CA3106510A1 (en) * 2018-07-19 2020-01-23 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
CA3155260A1 (en) * 2019-09-26 2021-04-01 The Board Of Trustees Of The Leland Stanford Junior Unversity Methods for reducing rewarding effects of morphine without affecting its analgesic effects
IL297470A (en) 2020-04-21 2022-12-01 H Lundbeck As Synthesis of a monoacylglycerol lipase inhibitor
US11434222B2 (en) 2020-11-13 2022-09-06 H. Lundbeck A/S MAGL inhibitors
CA3214469A1 (en) 2021-04-01 2022-10-06 Ono Pharmaceutical Co., Ltd. Abhd6 antagonist
AU2022426844A1 (en) 2021-12-29 2024-07-04 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
IL316302A (en) 2022-05-04 2024-12-01 H Lundbeck As Crystalline form of 111333-hexafluoropro s-1-pyridazin-3-ylca azaspiro2.5octane-6- as a monoacylglycerol lipase inhibitor
JP2024052624A (ja) * 2022-09-30 2024-04-11 小野薬品工業株式会社 Abhd6アンタゴニストを含有する医薬組成物
WO2024168426A1 (en) 2023-02-13 2024-08-22 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100326D0 (sv) * 2001-02-02 2001-02-02 Astrazeneca Ab New compounds
JP2004529113A (ja) * 2001-03-07 2004-09-24 ファイザー・プロダクツ・インク ケモカイン受容体活性のモジュレーター
MX2010009727A (es) * 2008-03-05 2010-09-28 Targacept Inc Amidas selectivas del subtipo del receptor nicotinico de acetilcolina de diazabicicloalcanos.
HUE043962T2 (hu) * 2009-10-23 2019-09-30 Janssen Pharmaceutica Nv Diszubsztituált oktahidro-pirrolo[3,4-C]pirrolok mint orexin receptor modulátorok
EP2542083B1 (en) * 2010-03-04 2015-05-06 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
EP2444084A1 (en) * 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
AR092645A1 (es) * 2012-09-25 2015-04-29 Hoffmann La Roche Derivados biciclicos inhibidores de autotaxina (atx)
CA2917050A1 (en) 2013-07-03 2015-01-08 Todd K. Jones Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof

Similar Documents

Publication Publication Date Title
JP2016525092A5 (enExample)
US12331056B2 (en) SHP2 phosphatase inhibitors and methods of use thereof
JP2018500376A5 (enExample)
JP6435323B2 (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
SI3083625T1 (en) Pyrimidopyrimidinones, useful as Wee-1 kinase inhibitors
JP2013523884A5 (enExample)
RU2019115115A (ru) Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7
JP2019535664A5 (enExample)
HRP20200575T1 (hr) Spojevi karbamata i postupci pripremanja i korištenja istih
JP2011511034A5 (enExample)
JP2015510938A5 (enExample)
JP2021506858A5 (enExample)
HRP20210177T1 (hr) Supstituirani spojevi pirazolo[1,5-a]piridina kao inhibitori ret kinaze
JP2011516558A5 (enExample)
FI3436461T3 (fi) Pyrrolotriatsiiniyhdisteitä tam-inhibiittoreina
JP2014506929A5 (enExample)
JPWO2020005873A5 (enExample)
JP2017530960A5 (enExample)
JP2015522002A5 (enExample)
RU2017105296A (ru) Новые соединения
HRP20210935T1 (hr) Spojevi 5-kloro-2-difluorometoksifenil pirazolopirimidina koji predstavljaju inhibitore jak
RU2005117383A (ru) Производные фенилаланина в качестве ингибиторов дипептидилпептидазы для лечения или профилактики диабета
JP2018527353A5 (enExample)
JPWO2020005877A5 (enExample)
JP2016507551A5 (enExample)